Provided by Tiger Fintech (Singapore) Pte. Ltd.

eFFECTOR Therapeutics, Inc.

0.0001
0.0000
Volume:3.00
Turnover:3.00
Market Cap:470.44
PE:0.00
High:0.0001
Open:0.0001
Low:0.0001
Close:0.0001
Loading ...

Company Profile

Company Name:
eFFECTOR Therapeutics, Inc.
Exchange:
EXPERT
Establishment Date:
2012
Employees:
14
Office Location:
142 North Cedros Avenue,Suite B,Solana Beach,California,United States
Zip Code:
92075
Fax:
- -
Introduction:
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.